Impact of hydroxychloroquine on pregnancy outcomes in systemic lupus erythematosus: A 25 years retrospective cohort study from Asia
- 8 February 2026
- journal article
- Published by SAGE Publications in Lupus
- Vol. 35 (5) , 516-523
Abstract
Background: Systemic lupus erythematosus (SLE) is an autoimmune disorder that affects various organs and follows a pattern of remission and relapse. Hydroxychloroquine (HCQ), an antimalarial drug, has recently become widely used in pregnant women with SLE due to its multi-level immune anti-inflammatory mechanisms and potential endothelial protective and thromboprophylaxis properties. While several studies have evaluated the impact of HCQ on SLE activity and the occurrence of neonatal lupus, its effects on improving early delivery, preeclampsia, and intrauterine growth restriction (IUGR) remain controversial. Objective: This study aims to determine the effect of HCQ on feto-maternal outcomes among pregnant women with SLE. Methodology: It is a retrospective cohort study over the past 25 years at Aga Khan Hospital, Karachi. The patients were divided into two groups. HCQ group had been taking HCQ throughout pregnancy. Non-HCQ group hadn’t been using HCQ. All statistical analysis was performed using SPSS version 19.0. For all tests, p ≤ .05 was considered statistically significant. Results: A total of 125 pregnant women with SLE were reviewed. The majority had conception in the remission period. There were 7 (20.6%) babies with fetal heart block in the non-HCQ group. The overall flare-up of disease was found in 68.8% (86/125), mostly in the third trimester. Positive anticardiolipin IgG antibodies were considerably higher in HCQ groups (47.25% vs 26.47%; p = .036). Conclusion: Our study findings suggest that maintaining disease remission prior to conception and continuing HCQ therapy during pregnancy may be associated with improved maternal and fetal outcomes, though the observed association with fetal heart block warrants cautious interpretation due to small numbers.Keywords
This publication has 23 references indexed in Scilit:
- The use of hydroxychloroquine in pregnancy and its effect on perinatal outcomes in a population with autoimmune abnormalitiesClinical Rheumatology, 2022
- Pregnancy-related complications in systemic lupus erythematosusJournal of Autoimmunity, 2022
- Birth Outcomes in Women Who Have Taken Hydroxycholoroquine During Pregnancy: A Prospective Cohort StudyArthritis & Rheumatology, 2021
- Low incidence of intrauterine growth restriction in pregnant patients with systemic lupus erythematosus taking hydroxychloroquineImmunological Medicine, 2021
- Hydroxychloroquine to Prevent Recurrent Congenital Heart Block in Fetuses of Anti-SSA/Ro-Positive MothersJACC, 2020
- Does Hydroxychloroquine Protect against Preeclampsia and Preterm Delivery in Systemic Lupus Erythematosus Pregnancies?American Journal of Perinatology, 2020
- The effect of lupus disease on the pregnant women and embryos: a retrospective study from 2010 to 2014Clinical Rheumatology, 2019
- Hydroxychloroquine for the prevention of fetal growth restriction and prematurity in lupus pregnancy: A systematic review and meta-analysisJoint Bone Spine, 2018
- Risk of venous and arterial thrombosis according to type of antiphospholipid antibodies in adults without systemic lupus erythematosus: A systematic review and meta-analysisAutoimmunity Reviews, 2014
- Lupus Activity in PregnancyRheumatic Disease Clinics of North America, 2007